Risk Factors for Hepatic Hydrothorax in Cirrhosis Patients with Ascites - A Clinical Cohort Study
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature..
BACKGROUND: The risk factors for hepatic hydrothorax are unknown.
METHODS: We used data from three randomized trials of satavaptan treatment in patients with cirrhosis and ascites followed for up to 1 year. We excluded patients with previous hepatic hydrothorax or other causes for pleural effusion. The candidate risk factors were age, sex, heart rate, mean arterial pressure, diuretic-resistant ascites, a recurrent need for paracentesis, diabetes, hepatic encephalopathy, International Normalized Ratio, creatinine, bilirubin, albumin, sodium, platelet count, use of non-selective beta-blockers (NSBBs), spironolactone, furosemide, proton pump inhibitors, and insulin. We identified risk factors using a Fine and Gray regression model and backward selection. We reported subdistribution hazard ratios (sHR) for hepatic hydrothorax. Death without hepatic hydrothorax was a competing risk.
RESULTS: Our study included 942 patients, of whom 41 developed hepatic hydrothorax and 65 died without having developed it. A recurrent need for paracentesis (sHR: 2.55, 95% CI: 1.28-5.08), bilirubin (sHR: 1.18 per 10 µmol/l increase, 95% CI: 1.09-1.28), diabetes (sHR: 2.49, 95% CI: 1.30-4.77) and non-use of non-selective beta-blockers (sHR: 2.27, 95% CI: 1.13-4.53) were risk factors for hepatic hydrothorax. Development of hepatic hydrothorax was associated with a high mortality-hazard ratio of 4.35 (95% CI: 2.76-6.97).
CONCLUSIONS: In patients with cirrhosis and ascites, risk factors for hepatic hydrothorax were a recurrent need for paracentesis, a high bilirubin, diabetes and non-use of NSBBs. Among these patients with cirrhosis and ascites, development of hepatic hydrothorax increased mortality fourfold.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:67 |
---|---|
Enthalten in: |
Digestive diseases and sciences - 67(2022), 7 vom: 11. Juli, Seite 3395-3401 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Deleuran, Thomas [VerfasserIn] |
---|
Links: |
---|
Themen: |
Adrenergic beta-Antagonists |
---|
Anmerkungen: |
Date Completed 29.06.2022 Date Revised 17.08.2022 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1007/s10620-021-07134-8 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM327380330 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM327380330 | ||
003 | DE-627 | ||
005 | 20231225200647.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s10620-021-07134-8 |2 doi | |
028 | 5 | 2 | |a pubmed24n1091.xml |
035 | |a (DE-627)NLM327380330 | ||
035 | |a (NLM)34191185 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Deleuran, Thomas |e verfasserin |4 aut | |
245 | 1 | 0 | |a Risk Factors for Hepatic Hydrothorax in Cirrhosis Patients with Ascites - A Clinical Cohort Study |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 29.06.2022 | ||
500 | |a Date Revised 17.08.2022 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. | ||
520 | |a BACKGROUND: The risk factors for hepatic hydrothorax are unknown | ||
520 | |a METHODS: We used data from three randomized trials of satavaptan treatment in patients with cirrhosis and ascites followed for up to 1 year. We excluded patients with previous hepatic hydrothorax or other causes for pleural effusion. The candidate risk factors were age, sex, heart rate, mean arterial pressure, diuretic-resistant ascites, a recurrent need for paracentesis, diabetes, hepatic encephalopathy, International Normalized Ratio, creatinine, bilirubin, albumin, sodium, platelet count, use of non-selective beta-blockers (NSBBs), spironolactone, furosemide, proton pump inhibitors, and insulin. We identified risk factors using a Fine and Gray regression model and backward selection. We reported subdistribution hazard ratios (sHR) for hepatic hydrothorax. Death without hepatic hydrothorax was a competing risk | ||
520 | |a RESULTS: Our study included 942 patients, of whom 41 developed hepatic hydrothorax and 65 died without having developed it. A recurrent need for paracentesis (sHR: 2.55, 95% CI: 1.28-5.08), bilirubin (sHR: 1.18 per 10 µmol/l increase, 95% CI: 1.09-1.28), diabetes (sHR: 2.49, 95% CI: 1.30-4.77) and non-use of non-selective beta-blockers (sHR: 2.27, 95% CI: 1.13-4.53) were risk factors for hepatic hydrothorax. Development of hepatic hydrothorax was associated with a high mortality-hazard ratio of 4.35 (95% CI: 2.76-6.97) | ||
520 | |a CONCLUSIONS: In patients with cirrhosis and ascites, risk factors for hepatic hydrothorax were a recurrent need for paracentesis, a high bilirubin, diabetes and non-use of NSBBs. Among these patients with cirrhosis and ascites, development of hepatic hydrothorax increased mortality fourfold | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Ascites | |
650 | 4 | |a Cirrhosis | |
650 | 4 | |a Diabetes | |
650 | 4 | |a Hepatic hydrothorax | |
650 | 4 | |a Non-selective beta-blockers | |
650 | 4 | |a Portal hypertension | |
650 | 7 | |a Adrenergic beta-Antagonists |2 NLM | |
650 | 7 | |a Bilirubin |2 NLM | |
650 | 7 | |a RFM9X3LJ49 |2 NLM | |
700 | 1 | |a Watson, Hugh |e verfasserin |4 aut | |
700 | 1 | |a Vilstrup, Hendrik |e verfasserin |4 aut | |
700 | 1 | |a Jepsen, Peter |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Digestive diseases and sciences |d 1989 |g 67(2022), 7 vom: 11. Juli, Seite 3395-3401 |w (DE-627)NLM000356492 |x 1573-2568 |7 nnns |
773 | 1 | 8 | |g volume:67 |g year:2022 |g number:7 |g day:11 |g month:07 |g pages:3395-3401 |
856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10620-021-07134-8 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 67 |j 2022 |e 7 |b 11 |c 07 |h 3395-3401 |